IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
KU Leuven · Hospital Clínic de Barcelona · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
219
total citations
- FWCI
- 63.58
- Percentile
- 100%
- References
- 167
Citations per year
Authors
22- BVBram Verstockt
KU Leuven
- ASAzucena Salas
Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
- BEBruce E. Sands
Icahn School of Medicine at Mount Sinai
- CAClara Abraham
Yale University
- HLHaim Leibovitzh
Mount Sinai Hospital, University of Toronto
Topics & keywords
Topics
Keywords
- Medicine
- Inflammatory bowel disease
- Inflammatory Bowel Diseases
- Interleukin 23
- Gastroenterology
- Disease
- Internal medicine
- Inflammation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- CCCleveland Clinic
- CCCleveland Clinic Foundation
- AUAmsterdam University Medical Centers
- UVUniversiteit van Amsterdam
- UOUniversity of Toronto
- KLKU Leuven
- HUHumanitas University
- HRHumanitas Research Hospital
- UOUniversity of California, San Diego
- LRLerner Research Institute, Cleveland Clinic
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAwards: DK120515, P30 DK120515